Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13101427 | 0.89 | HRH3 (0.49) | HRH3 | |
| SCHEMBL21871391 | 0.87 | HRH3 (0.43) | HRH3OPRM1OPRL1 | |
| SCHEMBL21871369 | 0.82 | HRH3 (0.40) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL26023136 | 0.79 | HRH3 (0.35) | HRH3OPRM1OPRL1TP53CHRM1 | |
| SCHEMBL21779953 | 0.79 | HRH3 (0.43) | HRH3 | |
| SCHEMBL21779876 | 0.79 | HRH3 (0.43) | HRH3 | |
| SCHEMBL23784287 | 0.79 | L3MBTL3 (0.42) | HRH3OPRM1OPRL1TP53 | |
| SCHEMBL22456358 | 0.77 | TSHR (0.40) | HRH3OPRM1OPRL1TP53TLR9 | |
| SCHEMBL23588628 | 0.76 | HRH3 (0.38) | HRH3TLR9TLR7 | |
| SCHEMBL23588761 | 0.76 | HRH3 (0.38) | HRH3TLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | HRH3 3238/4885OPRM1 3791/4885OPRL1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.